Neurobiology of Aging
Volume 31, Issue 5 , Pages 741-746 , May 2010

The PPAR-gamma Pro12Ala polymorphism and risk of cognitive impairment in a longitudinal study

  • Nancy A. West

      Affiliations

    • Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA
    • Present address: Department of Preventive Medicine and Biometrics, University of Colorado School of Medicine, Denver, CO 80246, USA.
    • ,
  • Mary N. Haan

      Affiliations

    • Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 734 615 9606; fax: +1 734 936 2079.
    • ,
  • Hal Morgenstern

      Affiliations

    • Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA
    • Department of Environmental Health Sciences, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA

Received 17 December 2007 ,Revised 22 May 2008 ,Accepted 7 June 2008.

References 

  1. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet. 2000;26:76–80
  2. Buzzetti R, Petrone A, Ribaudo MC, Alemanno I, Zavarella S, Mein CA, et al. The common PPAR-gamma2 Pro12Ala variant is associated with greater insulin sensitivity. Eur. J. Hum. Genet. 2004;
  3. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, et al Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 1994;7:180–184
  4. Cossrow N, Falkner B. Race/ethnic issues in obesity and obesity-related comorbidities. J. Clin. Endocrinol. Metab. 2004;89:2590–2594
  5. Craft S, Asthana S, Schellenberg G, Cherrier M, Baker LD, Newcomer J, et al. Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender. Neuroendocrinology. 1999;70:146–152
  6. Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology. 1998;50:164–168
  7. Gonzalez HM, Mungas D, Reed BR, Marshall S, Haan MN. A new verbal learning and memory test for English- and Spanish-speaking older people. J. Int. Neuropsychol. Soc. 2001;7:544–555
  8. Grootenhuis PA, Snoek FJ, Heine RJ, Bouter LM. Development of a type 2 diabetes symptom checklist: a measure of symptom severity. Diabet. Med. 1994;11:253–261
  9. Haan MN. Therapy insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. Nat. Clin. Pract. Neurol. 2006;2:159–166
  10. Haan MN, Mungas DM, Gonzalez HM, Ortiz TA, Acharya A, Jagust WJ. Prevalence of dementia in older latinos: the influence of type 2 diabetes mellitus, stroke and genetic factors. J. Am. Geriatr. Soc. 2003;51:169–177
  11. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, et al. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem. Biophys. Res. Commun. 2000;271:212–216
  12. Jorm AF, Jacomb PA. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol. Med. 1989;19:1015–1022
  13. Kalmijn S, Feskens EJ, Launer LJ, Stijnen T, Kromhout D. Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men. Diabetologia. 1995;38:1096–1102
  14. Koivisto AM, Helisalmi S, Pihlajamaki J, Hiltunen M, Koivisto K, Moilanen L, et al. Association analysis of peroxisome proliferator-activated receptor gamma polymorphisms and late onset Alzheimer's disease in the Finnish population. Dement. Geriatr. Cogn. Disord. 2006;22:449–453
  15. Kuusisto J, Koivisto K, Mykkanen L, Helkala EL, Vanhanen M, Hanninen T, et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ. 1997;315:1045–1049
  16. Laakso M. Insulin resistance and coronary heart disease. Curr. Opin. Lipidol. 1996;7:217–226
  17. Launer LJ. Diabetes and brain aging: epidemiologic evidence. Curr. Diab. Rep. 2005;5:59–63
  18. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology. 2004;63:1187–1192
  19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939–944
  20. Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J, et al. The Pro12→Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes. 2001;50:891–894
  21. Mori Y, Kim-Motoyama H, Katakura T, Yasuda K, Kadowaki H, Beamer BA, et al. Effect of the Pro12Ala variant of the human peroxisome proliferator-activated receptor gamma 2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men. Biochem. Biophys. Res. Commun. 1998;251:195–198
  22. Peila R, Rodriguez BL, White LR, Launer LJ. Fasting insulin and incident dementia in an elderly population of Japanese-American men. Neurology. 2004;63:228–233
  23. Razay G, Wilcock GK. Hyperinsulinaemia and Alzheimer's disease. Age Ageing. 1994;23:396–399
  24. Sauder S, Kolsch H, Lutjohann D, Schulz A, von Bergmann K, Maier W, et al. Influence of peroxisome proliferator-activated receptor gamma gene polymorphism on 24S-hydroxycholesterol levels in Alzheimer's patients. J. Neural Transm. 2005;112:1381–1389
  25. Scacchi R, Pinto A, Gambina G, Rosano A, Corbo RM. The peroxisome proliferator-activated receptor gamma (PPAR-gamma2) Pro12Ala polymorphism is associated with higher risk for Alzheimer's disease in octogenarians. Brain Res. 2007;
  26. Stefanski A, Majkowska L, Ciechanowicz A, Frankow M, Safranow K, Parczewski M, et al. Association between the Pro12Ala variant of the peroxisome proliferator-activated receptor-gamma2 gene and increased 24-h diastolic blood pressure in obese patients with type II diabetes. J. Hum. Hypertens. 2006;
  27. Teng EL, Chui HC. The modified mini-mental state (3MS) examination. J. Clin. Psychiatry. 1987;48:314–318
  28. Tierney MC, Black SE, Szalai JP, Snow WG, Fisher RH, Nadon G, et al. Recognition memory and verbal fluency differentiate probable Alzheimer disease from subcortical ischemic vascular dementia. Arch. Neurol. 2001;58:1654–1659
  29. Yaffe K, Kanaya AM, Lindquist K, Hsueh WC, Cummings SR, Beamer B, et al. PPAR-gamma Pro12Ala genotype and risk of cognitive decline in elders. Neurobiol. Aging. 2006;
  30. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, et al. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem. Biophys. Res. Commun. 1997;241:270–274
  31. Zietz B, Barth N, Spiegel D, Schmitz G, Scholmerich J, Schaffler A. Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma2 (PPARgamma2) is associated with higher levels of total cholesterol and LDL-cholesterol in male caucasian type 2 diabetes patients. Exp. Clin. Endocrinol. Diabetes. 2002;110:60–66

PII: S0197-4580(08)00211-X

doi: 10.1016/j.neurobiolaging.2008.06.005

Neurobiology of Aging
Volume 31, Issue 5 , Pages 741-746 , May 2010

Article Tools